May 13, 2022

An open letter to the respiratory community,

The Blade team and I are delighted that the American Thoracic Society (ATS) 2022 International Conference has arrived – live and in-person – in the Bay Area that we call “home.”

We look forward to interacting with you, the experts who work tirelessly to find new solutions for lung diseases, including for people living with the progressive, debilitating effects of lung fibrosis. As a clinician, scientist, and former academic anesthesiologist, I have seen patients struggling with acute and chronic respiratory diseases. I share your hope and commitment to find new pharmacologic options to improve patient outcomes.

Blade has deep expertise in novel biological pathways that are foundational to cell- and tissue-damage responses that underly fibrosis. We believe that our focused approach offers the potential to produce disease-modifying, life-saving therapies.

In recent months, Blade has thoughtfully and carefully advanced our lung fibrosis research with the best interests of patients first and foremost in our minds. During ATS, we will present encouraging clinical and preclinical data from our development program. We are ready to move forward into the next phase of clinical development based on those results.

Blade’s mission is to bring life-changing treatments to patients. The team and I believe that nothing matters more than helping people overcome illness and regain normal, productive, happier lives. We are committed to working with you to achieve those ends.

If you plan to attend the 2022 ATS in person, I invite you to stop by our exhibit booth. We would love to hear from you. I also invite you to connect with Blade on LinkedIn or at

Respectfully yours,


Wendye Robbins, M.D.
President and CEO
Blade Therapeutics